Original article by Jared Lynch
The Australian – Page: 17 & 27 : 13-Feb-20
CSL has posted a 2019-20 interim net profit of $US1.248bn, which is eight per cent higher than previously. Sales rose by 8.4 per cent to $US4.7bn, with sales of its immunoglobulin products rising by 26 per cent to $US1.985bn. The biotechnology group expects its full-year profit to be within the range of $US2.1bn to $US2.17bn. CEO Paul Perreault says none of the company’s employees in Wuhan have been infected by the coronavirus and the company has not yet been impacted by the outbreak.
CSL LIMITED – ASX CSL
Original article by Yolanda Redrup
The Australian Financial Review – Page: 15 : 15-Aug-19
Blood product company CSL released its results for the year to 30 June on 14 August, reporting a net profit after tax of $US1.92 billion ($2.9 billion), up 11 per cent. CSL’s revenue was up by 7.9 per cent to $US8.5 billion, while the company advised that it expected its net profit to exceed $US2 billion in the 2019-20 financial year. CSL CEO Paul Perreault called on its competitors in the global immunoglobulin market to boost their output, or risk demand significantly outweighing supply.
CSL LIMITED – ASX CSL
Original article by Sarah-Jane Tasker
The Australian – Page: 19 : 29-Aug-17
CSL has announced that it will spend $US91 million ($A114 million) on the purchase of US-based biotechnology company Calimmune. CSL executive Andrew Nash says the purchase of Calimmune gives it access to skills and technologies in the area of gene and cell-based therapies that it does not currently have. He said that CSL has had its eye on Calimmune, which has operations in both the US and Australia, for about a year.
CSL LIMITED – ASX CSL, CALIMMUNE INCORPORATED
Original article by Ben Potter
The Australian Financial Review – Page: 17 & 22 : 18-Aug-16
CSL has posted a 2015-16 net profit of $US1.24bn ($A1.6bn), which is 10 per cent lower than previously. The blood products and vaccines group’s sales rose by eight per cent to $US6.13bn. Earnings per share fell by eight per cent to $US2.69, but increased by seven per cent on a constant currency basis. CSL has forecast underlying net profit and EBITDA growth of 11 per cent and 14 per cent respectively in 2016-17. Its shares closed five per cent lower at $A110.84 on 17 August 2016.
CSL LIMITED – ASX CSL, SHIRE PHARMACEUTICALS GROUP PLC, NOVARTIS AG, CSL BEHRING, WILSONS ADVISORY AND STOCKBROKING LIMITED, SEQIRUS PTY LTD
Original article by Tim Binsted
The Australian Financial Review – Page: 15 : 16-Oct-15
Australian-listed CSL forecasts that its Seqirus influenza division will post revenue of $US450m and a break-even profit in 2015-16, before making a profit in 2017-18. Seqirus has been established by merging the BioCSL division with the recently acquired flu vaccines arm of Novartis. Meanwhile, CSL will repurchase some $A1bn of its shares over the next year. It will be the group’s ninth buyback in the last decade.
CSL LIMITED – ASX CSL, BIOCSL, SEQIRUS, NOVARTIS AG, UBS HOLDINGS PTY LTD
Original article by Jennifer Hewett
The Australian Financial Review – Page: 2 : 4-Aug-15
CSL is one of Australia’s most successful companies. It is a global player in the field of biotechnology. CFO Gordon Naylor complains about high tax rates in Australia which, he believes, hinder the development of the country’s advanced manufacturing sector. CSL advocates the introduction of a new tax rate of 10 per cent for advanced manufacturing. Under the current tax regime, Australian companies pay 30 per cent in corporate tax.
CSL LIMITED – ASX CSL, BLOOMBERG LP, AUSTRALIA. DEPT OF INDUSTRY AND SCIENCE
Original article by Joanna Mather
The Australian Financial Review – Page: 6 : 16-Jun-15
CSL’s CFO Gordon Naylor says the blood products group does not intend to reduce its manufacturing presence in Australia. However, he has conceded that CSL would have seriously considered building a $A500m plant in Australia if the nation’s 30 per cent corporate tax rate had been more competitive. CSL opted to build the facility in Switzerland, which has a company tax rate of 18 per cent. CSL has suggested that Australia adopt a tax rate of 10 per cent for advanced manufacturers.
CSL LIMITED – ASX CSL, CORPORATE TAX ASSOCIATION, MINERALS COUNCIL OF AUSTRALIA, ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT
Original article by Misa Han
The Australian Financial Review – Page: 22 : 6-Mar-15
Shares in CSL are trading at $A92.18, and there is speculation that the stock will breach the $A100 level. Goldman Sachs is among the CSL bulls, with a share price target of $A107, although the average 12-month share price target of analysts polled by Bloomberg is just $A90.23. CSL shares rose above $A100 in September 2007, although the group then opted for a stock split. Wilson HTM Investment Group says it could do so again if the stock reaches $A100
CSL LIMITED – ASX CSL, GOLDMAN SACHS AND PARTNERS AUSTRALIA PTY LTD, BLOOMBERG LP, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, RIO TINTO LIMITED – ASX RIO, COMMONWEALTH BANK OF AUSTRALIA – ASX CBA, DEUTSCHE BANK AG, SONIC HEALTHCARE LIMITED – ASX SHL, RESMED INCORPORATED – ASX RMD, HEALTHSCOPE LIMITED – ASX HSO, ANSELL LIMITED – ASX ANN, NIB HOLDINGS LIMITED – ASX NHF, RAMSAY HEALTH CARE LIMITED – ASX RHC, COCHLEAR LIMITED – ASX COH, MEDIBANK PRIVATE LIMITED – ASX MPL, STANDARD AND POOR’S ASX 200 INDEX
Original article by Philip Baker
The Australian Financial Review – Page: 30 : 12-Feb-15
The market capitalisation of Apple rose to $US711bn on 11 February 2015, and the IT giant may be on track to become the first company to achieve a market value of $US1trn. Apple shares have risen by more than 50,600 per cent since its IPO in 1980. Meanwhile, shares in Australian-listed Commonwealth Bank and CSL retreated on 11 February, although both remain close to record highs and are candidates to reach $A100 per share
COMMONWEALTH BANK OF AUSTRALIA – ASX CBA, CSL LIMITED – ASX CSL, APPLE INCORPORATED, EXXONMOBIL CORPORATION, GOOGLE INCORPORATED, MICROSOFT CORPORATION, WESTPAC BANKING CORPORATION – ASX WBC, UNIVERSITY OF MELBOURNE. INSTITUTE OF APPLIED ECONOMIC AND SOCIAL RESEARCH
Original article by Jessica Gardner
The Australian Financial Review – Page: 21 & 26 : 12-Feb-15
Australian-listed CSL has posted a 2014-15 interim net profit of $US692.2m, which is 7.2 per cent higher than previously. Revenue for the half-year was $A2.8bn, an increase of 5.6 per cent. CSL has advised that its full-year profit will be below previous guidance, although it is still on track to deliver a double-digit increase in earning. Shareholders will receive a half-year dividend of $US0.58 per share
CSL LIMITED – ASX CSL, UBS HOLDINGS PTY LTD, PHILO CAPITAL ADVISERS PTY LTD, UNITED STATES. FOOD AND DRUG ADMINISTRATION, AURORA FUNDS MANAGEMENT LIMITED, STANDARD AND POOR’S ASX 200 INDEX